SCHEMBL5029286

SCHEMBL5029286

CC(C)[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1NC(=O)CNC(=O)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
CCR2 P41597 8/20 0.51
CYP2D6 P10635 6/20 0.51
KCNH2 Q12809 5/20 0.51
CYP3A4 P08684 2/20 0.46
CCR5 P51681 1/20 0.44
TSHR P16473 1/20 0.43
CPB1 P15086 2/20 0.42
KDM1A O60341 1/20 0.42
RCOR1 Q9UKL0 1/20 0.42
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5030519 0.95 CCR2 (0.53) ALDH1A1CCR2CYP2D6KCNH2CYP3A4
SCHEMBL5033696 0.86 CCR2 (0.61) ALDH1A1CCR2CYP2D6KCNH2CYP3A4
SCHEMBL5033692 0.86 CCR2 (0.61) ALDH1A1CCR2CYP2D6KCNH2CYP3A4
SCHEMBL5029290 0.86 ALDH1A1 (0.49) ALDH1A1CCR2CYP2D6KCNH2CYP3A4
SCHEMBL5029280 0.86 ALDH1A1 (0.49) ALDH1A1CCR2CYP2D6KCNH2CYP3A4
SCHEMBL5030442 0.84 ALDH1A1 (0.67) ALDH1A1CCR2CYP2D6KCNH2CYP3A4
SCHEMBL5030435 0.84 ALDH1A1 (0.67) ALDH1A1CCR2CYP2D6KCNH2CYP3A4
SCHEMBL5027183 0.83 ALDH1A1 (0.57) ALDH1A1CCR2CYP3A4TSHRCPB1
SCHEMBL5027188 0.83 ALDH1A1 (0.57) ALDH1A1CCR2CYP3A4TSHRCPB1
SCHEMBL5030522 0.79 CCR2 (0.44) CCR2CYP2D6KCNH2CCR5CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7378409-B2 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY (US) 2008-05-27 US disclosed
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity BRISTOL-MYERS SQUIBB COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054626-A1 Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity CCL11, CCR1, CCR2 ALDH1A1 827/4885CCR2 3/4885CYP2D6 3033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.